Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The pathogenesis of Alzheimer disease (AD) remains a work in progress even as we approach the 50-year anniversary of the modern exploration of late-life dementia. The β-amyloid (Aβ) peptide has been a target of repeated therapeutic efforts for the last 2 decades. It seems like an obvious target: people dying with dementia often have high burdens of Aβ in one form or another throughout their brains. Over the last decade, several large clinical trials attempted to lower brain Aβ levels. One of them, with the anti-amyloid monoclonal antibody bapineuzumab, serves as the basis of a report in this issue of Neurology® .1
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The failure of these clinical trials may reflect the relatively late initiation of treatment or that the antibody load was not enough to clear sufficient amyloid-ß to yield clinical benefit.”
From Glymphatic failure as a final common pathway to dementia (2020) · cites this paper as [77]
Citations
Cites
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“The relationship of ARIA-E to APOE e4 is pertinent because the ApoE e4 protein is associated with the slowest brain clearance of Aβ.(5) Perhaps the longer time that Aβ lingers in paravascular spaces(6) both facilitates the clearance of Aβ by bapineuzumab and induces an inflammatory reaction that sometimes manifests as…”
BackgroundJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationRates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · cited 1×
“Brain volume loss was seen previously in an active anti-amyloid immune therapy trial.(10) The investigators in that earlier trial speculated that Aβ removal was of sufficient magnitude to account for the volumetric changes, and it seems plausible that Aβ is spaceoccupying in the cortex.”
BackgroundBiomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 44
Cited by
Glymphatic failure as a final common pathway to dementia
Nedergaard, M., & Goldman, S. A. (2020) · Science · doi:10.1126/science.abb8739 · Cited by 1,145
The Brain’s Glymphatic System: Current Controversies
Mestre, H., Mori, Y., & Nedergaard, M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.04.003 · Cited by 609
When I use a word . . . . Too much healthcare—Biomarkers
Aronson, J. K. (2022) · BMJ · doi:10.1136/bmj.o2533 · Cited by 5
What’s in a Name? Alzheimer’s Reimagined
Gibbs, D., & Barker, T. H. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009330961.022
When ARIA Is More than an Operatic Solo
Gibbs, D., & Barker, T. H. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009330961.015
Metadata
- Authors
- Knopman, D. S.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Knopman, David S.
- ORCID
- Knopman, David S.
- Venue
- Neurology
- Published
- 2018-03-06
- Volume
- 90
- Issue
- 10
- Pages
- 447-448
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2786312344
- Cited by
- 5
- References
- 10
- Citations by year
- 2022: 3 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Biogen
- Mayo Foundation for Medical Education and Research
- H. Lundbeck A/S
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, bapineuzumab, anti-amyloid monoclonal antibodies, amyloid-beta, anti-amyloid therapy, clinical trial failure, late-onset dementia, Alzheimer disease pathogenesis
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened. https://app.cochat.ai/papers/10.1212/wnl.0000000000005073
- The paper
- Knopman, D. S. (2018). Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened. Neurology. https://doi.org/10.1212/wnl.0000000000005073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.